PTCT - PTCセラピュ―ティクス (PTC Therapeutics Inc.)

PTCTのニュース

   PTC Therapeutics Earnings Report: Here’s what to expect from Stock market Insights & financial analysis  2021/02/24 14:28:00 Stock Market Daily
PTC Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   RBC Capital Stick to Their Sell Rating for PTC Therapeutics By Investing.com  2021/01/14 09:09:21 Investing.com
RBC Capital Stick to Their Sell Rating for PTC Therapeutics
   Duchenne Muscular Dystrophy (DMD) Treatment Market Latest Insights By Major Key Players SUMMIT Therapeutics Plc., PTC Therapeutics, BioMarin Pharmaceuticals Incorporated, Sarepta Therapeutics, Pfizer Incorporated, Pharmacia & Upjohn LLC  2021/01/14 06:14:40 OpenPR
The Duchenne Muscular Dystrophy (DMD) Treatment Market is expected to have a highly positive outlook over the forecast period 2020-2027 according to a Duchenne Muscular Dystrophy (DMD) Treatment Market research report. The Duchenne Muscular Dystrophy (DMD) Treatment report stresses the
   Ptc Therapeutics Inc (PTCT) CEO Stuart Walter Peltz Sold $1.2 million of Shares  2020/12/10 02:15:05 Yahoo Finance
CEO of Ptc Therapeutics Inc (30-Year Financial, Insider Trades) Stuart Walter Peltz (insider trades) sold 20,017 shares of PTCT on 12/07/2020 at an average price of $61.42 a share.
   PTC Therapeutics Reviews Inducement Grants Below Nasdaq Itemizing Rule 5635(c)(4)  2020/12/05 00:54:12 Fintech Zoom
PTC Therapeutics Reviews Inducement Grants Below Nasdaq Itemizing Rule 5635(c)(4) -
   PTC Therapeutics Earnings Report: Here’s what to expect from Stock market Insights & financial analysis  2021/02/24 14:28:00 Stock Market Daily
PTC Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   RBC Capital Stick to Their Sell Rating for PTC Therapeutics By Investing.com  2021/01/14 09:09:21 Investing.com
RBC Capital Stick to Their Sell Rating for PTC Therapeutics
   Duchenne Muscular Dystrophy (DMD) Treatment Market Latest Insights By Major Key Players SUMMIT Therapeutics Plc., PTC Therapeutics, BioMarin Pharmaceuticals Incorporated, Sarepta Therapeutics, Pfizer Incorporated, Pharmacia & Upjohn LLC  2021/01/14 06:14:40 OpenPR
The Duchenne Muscular Dystrophy (DMD) Treatment Market is expected to have a highly positive outlook over the forecast period 2020-2027 according to a Duchenne Muscular Dystrophy (DMD) Treatment Market research report. The Duchenne Muscular Dystrophy (DMD) Treatment report stresses the
   Ptc Therapeutics Inc (PTCT) CEO Stuart Walter Peltz Sold $1.2 million of Shares  2020/12/10 02:15:05 Yahoo Finance
CEO of Ptc Therapeutics Inc (30-Year Financial, Insider Trades) Stuart Walter Peltz (insider trades) sold 20,017 shares of PTCT on 12/07/2020 at an average price of $61.42 a share.
   PTC Therapeutics Reviews Inducement Grants Below Nasdaq Itemizing Rule 5635(c)(4)  2020/12/05 00:54:12 Fintech Zoom
PTC Therapeutics Reviews Inducement Grants Below Nasdaq Itemizing Rule 5635(c)(4) -
   PTC Therapeutics Earnings Report: Here’s what to expect from Stock market Insights & financial analysis  2021/02/24 14:28:00 Stock Market Daily
PTC Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   RBC Capital Stick to Their Sell Rating for PTC Therapeutics By Investing.com  2021/01/14 09:09:21 Investing.com
RBC Capital Stick to Their Sell Rating for PTC Therapeutics
   Duchenne Muscular Dystrophy (DMD) Treatment Market Latest Insights By Major Key Players SUMMIT Therapeutics Plc., PTC Therapeutics, BioMarin Pharmaceuticals Incorporated, Sarepta Therapeutics, Pfizer Incorporated, Pharmacia & Upjohn LLC  2021/01/14 06:14:40 OpenPR
The Duchenne Muscular Dystrophy (DMD) Treatment Market is expected to have a highly positive outlook over the forecast period 2020-2027 according to a Duchenne Muscular Dystrophy (DMD) Treatment Market research report. The Duchenne Muscular Dystrophy (DMD) Treatment report stresses the
   Ptc Therapeutics Inc (PTCT) CEO Stuart Walter Peltz Sold $1.2 million of Shares  2020/12/10 02:15:05 Yahoo Finance
CEO of Ptc Therapeutics Inc (30-Year Financial, Insider Trades) Stuart Walter Peltz (insider trades) sold 20,017 shares of PTCT on 12/07/2020 at an average price of $61.42 a share.
   PTC Therapeutics Reviews Inducement Grants Below Nasdaq Itemizing Rule 5635(c)(4)  2020/12/05 00:54:12 Fintech Zoom
PTC Therapeutics Reviews Inducement Grants Below Nasdaq Itemizing Rule 5635(c)(4) -

calendar